Anabolic Steroids Blog - iSteroids . com » Corticosteroids effective than Remicade for remission induction in Ulcerative Colitis patients

Corticosteroids effective than Remicade for remission induction in Ulcerative Colitis patients

Corticosteroids effective than Remicade for remission induction in Ulcerative Colitis patients Abbott/Eisai’s Humira is about to earn Gold Standard Status for Ulcerative Colitis in 2012 as per a report from Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues.

It was revealed by Decision Resources that the surveying gastroenterologists have been successful in ascertaining the effect of a therapy on remission induction and this effect is hailed as a critical attribute in positively influencing research decisions in moderate to severe ulcerative colitis (UV). It was also revealed that corticosteroids have an advantage over Remicade in this attribute.

From Bio-Medicine.Org:

The new report entitled Ulcerative Colitis: Opportunity Awaits Therapies That Treat Moderate to Severe Disease More Effectively Than Infliximab finds that a drug that maintains remission in a higher percentage of patients with moderate to severe ulcerative colitis than infliximab at one year would earn a 30 percent patient share in the United States and a 15 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists.

In 2008, Decision Resources’ proprietary clinical gold standard for ulcerative colitis was prednisone. Based on available data and expert opinion, Abbott/Eisai’s Humira (adalimumab) will earn gold-standard status for ulcerative colitis in 2012, following its approval for the indication in 2011. Interviewed experts believe that adalimumab has potential to be superior in maintenance of remission when compared to infliximab.

It was remarked by Decision Resources Analyst Benjamin Guikema, Ph.D., that adalimumab is believed to be more effective than infliximab when it comes to the maintenance setting. It was suggested that adalimumab is superior as well as more tolerable than any other available drugs in the present day market. The fact that Adalimumab offers a minimized risk of prominent organ also goes in its favor over other drugs.